# Altamira Therapeutics Ltd. (CYTO)

Source: https://www.quantisnow.com/company/CYTO
Generated: 2026-11-14T07:17:07.697Z

- Ticker: CYTO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014

## Latest CYTO news and filings

- 2024-12-20 13:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-altamira-therapeutics-ltd-5821493)
- 2024-12-20 13:00 UTC [Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets](https://www.quantisnow.com/insight/altamira-therapeutics-announces-transition-from-nasdaq-to-otc-markets-5821486)
- 2024-11-14 20:27 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-altamira-therapeutics-ltd-5775106)
- 2024-10-04 20:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-altamira-therapeutics-ltd-5716938)
- 2024-10-04 20:01 UTC [Altamira Therapeutics Provides Update on Nasdaq Listing](https://www.quantisnow.com/insight/altamira-therapeutics-provides-update-on-nasdaq-listing-5716928)
- 2024-09-27 13:01 UTC [Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray](https://www.quantisnow.com/insight/altamira-therapeutics-announces-extended-iso-13485-quality-management-system-certification-5706724)
- 2024-09-24 12:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-altamira-therapeutics-ltd-5702960)
- 2024-09-24 12:01 UTC [Public Offering] [Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results](https://www.quantisnow.com/insight/altamira-therapeutics-provides-business-update-and-first-half-2024-financial-5702922)
- 2024-09-20 13:01 UTC [Leadership Update] [Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024](https://www.quantisnow.com/insight/altamira-therapeutics-to-host-first-half-2024-financial-results-and-5700505)
- 2024-09-19 20:17 UTC [SEC Form 6-K] [SEC Form 6-K filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-altamira-therapeutics-ltd-5699712)
- 2024-09-19 20:01 UTC [Public Offering] [Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering](https://www.quantisnow.com/insight/altamira-therapeutics-announces-closing-of-up-to-120-million-public-5699546)
- 2024-09-18 20:19 UTC [SEC Form 424B4 filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/sec-form-424b4-filed-by-altamira-therapeutics-ltd-5698244)
- 2024-09-18 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-altamira-therapeutics-ltd-5697448)
- 2024-09-17 21:00 UTC [Public Offering] [Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering](https://www.quantisnow.com/insight/altamira-therapeutics-announces-pricing-of-up-to-120-million-public-5696855)
- 2024-09-16 17:55 UTC [SEC Form F-1] [Amendment: SEC Form F-1/A filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/amendment-sec-form-f-1a-filed-by-altamira-therapeutics-ltd-5694801)
- 2024-09-16 13:29 UTC [SEC Form F-1] [Amendment: SEC Form F-1/A filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/amendment-sec-form-f-1a-filed-by-altamira-therapeutics-ltd-5694635)
- 2024-09-16 12:30 UTC [Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia](https://www.quantisnow.com/insight/altamira-therapeutics-announces-expansion-of-bentrio-license-and-distribution-agreement-5694476)
- 2024-09-03 13:01 UTC [Conference Announcement] [Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11](https://www.quantisnow.com/insight/altamira-therapeutics-to-present-at-hc-wainwright-26th-annual-global-5679339)
- 2024-08-26 12:00 UTC [Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)](https://www.quantisnow.com/insight/diamond-equity-research-releases-update-note-on-altamira-therapeutics-ltd-5671330)
- 2024-08-23 13:01 UTC [Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark](https://www.quantisnow.com/insight/altamira-therapeutics-announces-extension-of-bentrio-distribution-agreement-with-pharma-5670198)
- 2024-08-22 20:53 UTC [SEC Form F-1] [SEC Form F-1 filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/sec-form-f-1-filed-by-altamira-therapeutics-ltd-5669574)
- 2024-08-16 13:01 UTC [Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances](https://www.quantisnow.com/insight/altamira-therapeutics-announces-confirmed-suitability-of-bentrio-for-athletes-as-5662385)
- 2024-08-12 13:02 UTC [Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models](https://www.quantisnow.com/insight/altamira-therapeutics-announces-significant-enhancement-of-immune-checkpoint-inhibition-therapy-5654316)
- 2024-07-19 13:03 UTC [Market Chatter] [Altamira Therapeutics Publishes Preclinical Data For Treatment Of Abdominal Aortic Aneurysm With SOD2 mRNA Delivered By SemaPhore Nanoparticles](https://www.quantisnow.com/insight/altamira-therapeutics-publishes-preclinical-data-for-treatment-of-abdominal-aortic-5617128)
- 2024-07-19 13:01 UTC [Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles](https://www.quantisnow.com/insight/altamira-therapeutics-announces-publication-of-preclinical-data-showing-successful-treatment-5617111)
- 2024-07-15 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-altamira-therapeutics-ltd-5607103)
- 2024-07-08 21:17 UTC [SEC Form POS AM filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-altamira-therapeutics-ltd-5597933)
- 2024-07-01 11:08 UTC [Amendment: SEC Form 20-F/A filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/amendment-sec-form-20-fa-filed-by-altamira-therapeutics-ltd-5585187)
- 2024-06-20 13:05 UTC [Market Chatter] [Altamira Therapeutics Highlights Review Article Published On Use Of Betahistine In Vertigo Management](https://www.quantisnow.com/insight/altamira-therapeutics-highlights-review-article-published-on-use-of-betahistine-5567583)
- 2024-06-20 13:01 UTC [Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management](https://www.quantisnow.com/insight/altamira-therapeutics-highlights-newly-published-review-article-supporting-use-of-5567556)
- 2024-05-28 14:33 UTC [Market Chatter] [Altamira Therapeutics Provides Business Update On RNA Delivery Platform; Announces Improvement In RNA Nanoparticle Stability, Pursues Partnering Opportunities For AM-125 In Vertigo And CNS Indications, And Switches Financial Reporting From Swiss Francs To US Dollars](https://www.quantisnow.com/insight/altamira-therapeutics-provides-business-update-on-rna-delivery-platform-announces-5519255)
- 2024-05-28 14:31 UTC [Altamira Therapeutics Provides Business Update](https://www.quantisnow.com/insight/altamira-therapeutics-provides-business-update-5519244)
- 2024-05-23 16:31 UTC [Market Insight] [12 Health Care Stocks Moving In Thursday's Intraday Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-thursdays-intraday-session-5513086)
- 2024-05-23 16:21 UTC [Market Chatter] [Altamira Therapeutics shares are trading higher after highlights from its NASAR clinical trial with Bentrio nasal spray were published in video format on the social media channels of the journal, "Allergy."](https://www.quantisnow.com/insight/altamira-therapeutics-shares-are-trading-higher-after-highlights-from-its-5513064)
- 2024-05-23 16:20 UTC [Market Insight] [What's Going On With Altamira Therapeutics Stock?](https://www.quantisnow.com/insight/whats-going-on-with-altamira-therapeutics-stock-5513057)
- 2024-05-23 12:55 UTC [Market Chatter] [Altamira Therapeutics Announces Publication Of Highlights From The NASAR Clinical Trial On The Social Media Channels Of Allergy](https://www.quantisnow.com/insight/altamira-therapeutics-announces-publication-of-highlights-from-the-nasar-clinical-5512449)
- 2024-05-23 12:47 UTC [Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal](https://www.quantisnow.com/insight/altamira-therapeutics-announces-dissemination-of-positive-results-from-bentrio-trial-5512430)
- 2024-05-16 20:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Altamira Therapeutics Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-altamira-therapeutics-ltd-5497344)
- 2024-05-01 13:00 UTC [Market Chatter] [Altamira Therapeutics Announces Filing Of Provisional Patent Application For OligoPhore Nanoparticles With siRNA Targeting p65 Protein In Treatment Of Cancer And Inflammation](https://www.quantisnow.com/insight/altamira-therapeutics-announces-filing-of-provisional-patent-application-for-oligophore-5448008)
- 2024-05-01 12:47 UTC [Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation](https://www.quantisnow.com/insight/altamira-therapeutics-announces-filing-of-provisional-patent-application-for-oligophore-5447879)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CYTO
- Earnings history: https://www.quantisnow.com/earnings/CYTO
- Dividend history: https://www.quantisnow.com/dividends/CYTO
- Insider transactions: https://www.quantisnow.com/insiders/CYTO
- Options chain: https://www.quantisnow.com/options/CYTO
- SEC 8-K filings only: https://www.quantisnow.com/company/CYTO/8-k
- RSS and alerts for CYTO: https://www.quantisnow.com/docs/rss-feeds.md